Alice T Shaw Selected Research

Anaplastic Lymphoma Kinase

1/2022	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
11/2020	First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
1/2020	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
1/2020	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
1/2020	Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
1/2019	Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
1/2019	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
1/2019	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies.
1/2019	Clinical Management of Adverse Events Associated with Lorlatinib.
10/2018	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alice T Shaw Research Topics

Disease

80	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 10/2010
76	Neoplasms (Cancer) 01/2022 - 07/2005
52	Lung Neoplasms (Lung Cancer) 07/2022 - 07/2005
22	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2015
15	Disease Progression 01/2022 - 10/2012
12	Brain Neoplasms (Brain Tumor) 11/2020 - 02/2015
5	Diarrhea 12/2021 - 03/2014
4	Central Nervous System Diseases (CNS Diseases) 01/2018 - 12/2016
3	Edema (Dropsy) 07/2022 - 01/2019
3	Adenocarcinoma of Lung 01/2018 - 06/2013
3	Melanoma (Melanoma, Malignant) 01/2017 - 05/2014
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 09/2015 - 04/2011
2	Vomiting 12/2021 - 03/2014
2	Nausea 01/2021 - 07/2018
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2020 - 01/2019
2	Hyperlipidemias (Hyperlipidemia) 11/2020 - 01/2019
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 10/2019
2	Vision Disorders (Hemeralopia) 07/2018 - 06/2013
2	Pain (Aches) 01/2018 - 11/2014
2	Cough 01/2018 - 11/2014
2	Fatigue 11/2014 - 06/2013
2	Dyspnea (Shortness of Breath) 11/2014 - 06/2013
2	Neutropenia 01/2013 - 10/2012
1	Weight Gain 12/2021
1	Hypercholesterolemia 01/2019
1	Hypertriglyceridemia 01/2019
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2017
1	Glioma (Gliomas) 01/2017
1	Stroke (Strokes) 01/2017
1	Mammary Analogue Secretory Carcinoma 01/2017
1	Colorectal Neoplasms (Colorectal Cancer) 01/2017
1	Mesothelioma 01/2017
1	Respiratory Insufficiency (Respiratory Failure) 01/2017
1	Hypertension (High Blood Pressure) 12/2016
1	Interstitial Lung Diseases (Interstitial Lung Disease) 04/2016
1	Infections 04/2016
1	Hepatitis 04/2016
1	Meningeal Carcinomatosis 02/2016
1	Liver Failure 01/2016

Drug/Important Bio-Agent (IBA)

66	CrizotinibIBA 07/2022 - 10/2010
54	Anaplastic Lymphoma KinaseIBA 01/2022 - 10/2010
22	alectinibIBA 01/2022 - 11/2014
21	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2011
18	lorlatinibIBA 07/2022 - 07/2015
18	Phosphotransferases (Kinase)IBA 01/2019 - 03/2011
12	ceritinibIBA 01/2020 - 01/2014
10	Pharmaceutical PreparationsIBA 12/2017 - 03/2011
7	ErbB Receptors (EGF Receptor)IBA 01/2020 - 03/2011
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 03/2012
6	Circulating Tumor DNAIBA 10/2020 - 01/2017
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 10/2010
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2005
5	entrectinibIBA 01/2021 - 12/2015
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2015
4	Immune Checkpoint InhibitorsIBA 01/2019 - 09/2016
4	Tyrosine (L-Tyrosine)FDA Link 01/2017 - 03/2011
3	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2018
3	Biological ProductsIBA 10/2020 - 12/2018
3	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 03/2015
3	brigatinibIBA 10/2018 - 05/2011
3	Docetaxel (Taxotere)FDA Link 01/2017 - 01/2013
2	cabozantinibIBA 01/2021 - 01/2015
2	Alanine Transaminase (SGPT)IBA 01/2021 - 10/2012
2	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 01/2016
2	osimertinibIBA 01/2019 - 04/2016
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2017 - 12/2014
2	Pemetrexed (MTA)FDA Link 01/2017 - 11/2014
2	PlatinumIBA 01/2017 - 06/2013
2	rociletinibIBA 04/2016 - 07/2015
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016 - 10/2012
2	Transaminases (Aminotransferases)IBA 03/2014 - 06/2013
1	CholesterolIBA 12/2021
1	Triglycerides (Triacylglycerol)IBA 12/2021
1	capmatinibIBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	taletrectinibIBA 01/2020
1	Adenosine Triphosphatases (ATPase)IBA 01/2020
1	Temozolomide (Temodar)FDA LinkGeneric 10/2019
1	olaparibIBA 10/2019
1	vasectrin II (VS II)IBA 01/2019
1	vasectrin IIIIBA 01/2019
1	SolventsIBA 10/2018
1	repotrectinibIBA 10/2018
1	NivolumabIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 12/2017
1	Complement System Proteins (Complement)IBA 12/2017
1	Aligeron (AS 2)IBA 01/2017
1	pembrolizumabIBA 01/2017
1	Mitogen-Activated Protein KinasesIBA 01/2017
1	Lipase (Acid Lipase)FDA Link 12/2016
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2016
1	Proto-Oncogene Proteins c-metIBA 01/2016
1	tyrosine receptor (receptor, tyrosine)IBA 01/2016

Therapy/Procedure

43	Therapeutics 11/2021 - 03/2011
9	Drug Therapy (Chemotherapy) 01/2019 - 06/2013
7	Radiotherapy 10/2018 - 02/2015
5	Immunotherapy 01/2018 - 01/2015
2	Drug Tapering 07/2022 - 02/2015
2	Aftercare (After-Treatment) 01/2020 - 02/2015
1	Molecular Targeted Therapy 01/2017